Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models
Charest, Alain
Neuro-oncology (Charlottesville, Va.), 2022-03, Vol.24 (3), p.396-397 [Periódico revisado por pares]US: Oxford University Press
Texto completo disponível